Immune Profiling of Dermatologic Adverse Events from Checkpoint Blockade Using Tissue Cyclic Immunofluorescence: A Pilot Study

J Invest Dermatol. 2024 Aug;144(8):1887-1890.e5. doi: 10.1016/j.jid.2024.01.024. Epub 2024 Feb 14.

¹ Laboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.
² Harvard-MIT Health Sciences and Technology Program, Harvard Medical School, Boston, Massachusetts, USA.
³ Department of Dermatology, The Center for Cutaneous Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts, USA.
⁴ Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
⁵ Program in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
⁶ Department of Dermatology, The Center for Cutaneous Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts, USA. Electronic address: [email protected].

No abstract available

Keywords: Cutaneous adverse events; Immune checkpoint blockade; Immune-related adverse events; Immunotherapy; Tissue cyclic immunofluorescence.

Publication types